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The stimulatory effects of ghrelin, a 28-AA acylated peptide originally isolated from stom-
ach, on growth hormone (GH) secretion and feeding are exclusively mediated through the
growth hormone secretagogue 1a receptor (GHS-R1a), the only ghrelin receptor described
so far. Several GHS-R1a agonists and antagonists have been developed to treat metabolic
or nutritional disorders but their mechanisms of action in the central nervous system remain
poorly understood. In the present study, we compared the activity of BIM-28163, a GHS-
R1a antagonist, and of several agonists, including native ghrelin and the potent synthetic
agonist, BIM-28131, to modulate food intake, GH secretion, and cFos activity in arcuate
nucleus (ArcN), nucleus tractus solitarius (NTS), and area postrema (AP) in wild-type and
NPY-GFP mice. BIM-28131 was as effective as ghrelin in stimulating GH secretion, but more
active than ghrelin in inducing feeding. It stimulated cFos activity similarly to ghrelin in the
NTS and AP but was more powerful in the ArcN, suggesting that the super-agonist activity
of BIM-28131 is mostly mediated in the ArcN. BIM-28163 antagonized ghrelin-induced GH
secretion but not ghrelin-induced food consumption and cFos activation, rather it stimulated
food intake and cFos activity without affecting GH secretion.The level of cFos activation was
dependent on the region considered: BIM-28163 was as active as ghrelin in the NTS, but
less active in the ArcN and AP. All compounds also induced cFos immunoreactivity in ArcN
NPY neurons but BIM-28131 was the most active. In conclusion, these data demonstrate
that two peptide analogs of ghrelin, BIM-28163, and BIM-28131, are powerful stimulators
of appetite in mice, acting through pathways and key brain regions involved in the control
of appetite that are only partially superimposable from those activated by ghrelin. A better
understanding of the molecular pathways activated by these compounds could be useful
in devising future therapeutic applications, such as for cachexia and anorexia.
Keywords: ghrelin, GHS-R, BIM-28163, BIM-28131, antagonist, food intake, GH secretion, cFos
INTRODUCTION
Ghrelin is a 28 amino acid acylated peptide originally discov-
ered in stomach tissues by inverse pharmacology (Kojima et al.,
1999) as the endogenous ligand for the growth hormone (GH)
Secretagogue-1a Receptor (GHS-R1a), an orphan receptor cloned
a few years earlier from pig pituitaries (Howard et al., 1996). GH
secretagogues are a family of synthetic peptidic or non-peptidic
compounds developed from the early 1980s to stimulate GH secre-
tion (Bluet-Pajot et al., 2001). As anticipated, ghrelin was initially
described for its ability to stimulate GH secretion in several species
including rodents and humans (Kojima et al., 1999; Tolle et al.,
2001) but it is still to date the only orexigenic hormone produced
in the gastrointestinal tract (Tschop et al., 2000).
The actions of ghrelin on GH secretion and feeding require the
addition of an eight-carbon fatty acid that is attached on a serine
in position 3 by the enzyme ghrelin-O-acyl-transferase (GOAT)
(Gutierrez et al., 2008; Yang et al., 2008). They are exclusively
mediated through the GHS-R1a (Sun et al., 2004), the only ghre-
lin receptor described so far. GHS-R1a is highly expressed in the
hypothalamus, a region involved in the control of GH secretion
and appetite, and also in the brainstem that receives informations
from gut vagal afferents (Guan et al., 1997; Katayama et al., 2000).
Within the hypothalamus, NPY neurons in the arcuate nucleus
(ArcN) express the GHS-R1a (Willesen et al., 1999; Tannenbaum
et al., 2003), and are a well-characterized target for ghrelin actions
(Tannenbaum et al., 2003; Chen et al., 2004). Nevertheless, sev-
eral studies have suggested that certain ghrelin actions may be
mediated through a receptor that has yet to be identified.
Several GHS-R1a antagonists have been developed to decipher
the function of the ghrelin/GHS-R pathway in the regulation of
feeding behavior and GH secretion (Asakawa et al., 2003; Okimura
et al., 2003; Beck et al., 2004; Halem et al., 2004; Demange et al.,
2007; Esler et al., 2007; Petersen et al., 2009; Costantini et al., 2011;
Moulin et al., 2013). Although they have all been clearly shown
to antagonize exogenous ghrelin actions on GH secretion both in
in vitro systems and in vivo, their biological effects per se on several
biological parameters are contradictory and their mechanisms of
action in the central nervous system remain poorly understood.
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Indeed, intracerebroventricular injections of two antagonists [d-
Lys3]-GHRP6, an analog of one of the synthetic GHS (Asakawa
et al., 2003) or [d-Arg-1, d-Phe-5, d-Trp-7,9,Leu-11]-substance P,
an analog of substance P (Petersen et al., 2009) induces suppression
of feeding in mice. In contrast [d-Lys3]-GHRP6 has no action on
spontaneous ultradian GH secretion (Okimura et al., 2003). But
results are biased by the fact that [d-Lys3]-GHRP6 also binds to
all melanocortin receptors (Schioth et al., 1997) and [d-Arg-1, d-
Phe-5, d-Trp-7,9,Leu-11]-substance P also has full inverse agonist
action in vitro and in vivo (Holst et al., 2003; Petersen et al., 2009).
To date, the effects of JMV2810, another recently developed GHS-
R1a antagonist, on spontaneous feeding or GH secretion have not
been reported (Demange et al., 2007).
Only the full-length ghrelin analog, BIM-28163 (now called
RM-28163), has been tested on both spontaneous GH secretion
and food intake. Treatment with this selective GHS-R1a antago-
nist over 48 h in rats reduces pulsatile GH secretion (Zizzari et al.,
2005). In contrast, it increases food intake and weight gain as effec-
tively as ghrelin when administered at 5- to 10-fold higher doses
than ghrelin (Halem et al., 2004, 2005). Interestingly, BIM-28163
induces cFos activation in the dorsomedial nucleus of the hypo-
thalamus (DMH) while it acts as an antagonist in the ArcN of
the hypothalamus. These data are corroborated by a more recent
study also describing a stimulatory effect of another GHS-R1a
antagonist, GSK1614343, on feeding in rats and dogs (Costan-
tini et al., 2011). Altogether these data are intriguing and suggest
the existence of an unknown pathway mediating the effects of
these ghrelin antagonists on feeding through either the GHS-R1a
or another unknown receptor. Understanding the mechanisms of
action of this compound that differentially affect feeding and GH
secretion can be of clinical interest.
In the present study, we compared the effect of BIM-28163,
BIM-28131(Strassburg et al., 2008; Palus et al., 2011), native ghre-
lin, and the combination of BIM-28163+ ghrelin in the modula-
tion of food intake, GH secretion, and cFos activity in fed mice.
Our aim was to map changes in cFos activation in several key
brain regions controlling appetite and/or GH secretion, including
the hypothalamic ArcN, ventromedial nucleus of the hypothala-
mus (VMH), nucleus tractus solitarius (NTS), and area postrema
(AP) of the brainstem. In addition, we used NPY-GFP mice to
test whether the feeding effects of the analogs were mediated, like
ghrelin, through the orexigenic NPY neurons.
MATERIALS AND METHODS
ANIMALS
About 18–25-week-old C57BL6/J male and female mice, obtained
either from Charles River or from our own colony, were used for
feeding experiments. About 18–25-week-old C57BL6/J or NPY-
Renilla GFP transgenic male and female mice backcrossed on
the C57BL6/J background and expressing Renilla GFP under the
transcriptional control of the NPY genomic sequence (Van Den
Pol et al., 2009) were used for cFos experiments. Mice were
housed at constant temperature and humidity, with a fixed 12-
h light/dark cycle (lights-on at 7.00 a.m.) and free access to food
and water. In addition, the animals were handled weekly to min-
imize stress. All experiments were carried out in accordance with
the European Communities Council Directive (86/609/EEC) and
were approved by the animal experimentation committee of Paris
Descartes University.
PEPTIDES
Native ghrelin, BIM-28131 (a small peptide ghrelin agonist),
and BIM-28163 (a full-length ghrelin analog antagonist) were
obtained from IPSEN (Milford, MA, USA). Peptides were dis-
solved in a vehicle containing 0.9% saline+0.25% of bovin serum
albumin (BSA).
AUTOMATED FOOD INTAKE MONITORING
One week prior to the experiments, 18–25-week-old C57BL6/J
male mice were individually housed and acclimatized to the auto-
mated drinking/feeding stations (TSE Systems, GmbH, Germany).
Feeding behavior was recorded continuously by means of high pre-
cision sensors, attached to the top of the cage lids. Meal patterns
were analyzed using the following definition: a meal consists of
the consumption of 0.03 g of food separated from the next feeding
episode by at least 10 min as previously described (Yu et al., 2009;
Stengel et al., 2010; Wang et al., 2011). For each mouse, the meal
number, the total meal size (g), and the total meal duration (min)
were measured within 4 h following peptide injections.
Experiments were performed during the light phase (10.00
a.m.–11.00 a.m.) and carried out in a cross-over designed manner
so that each mouse received all treatments randomly separated by
two washout days. On each experimental day, mice were injected
intraperitoneally (ip) with either vehicle (0.9% saline contain-
ing 0.25% BSA), native ghrelin (30 nmol), BIM-28131 (30 nmol),
BIM-28163 (150 nmol), or native ghrelin (30 nmol) combined
with BIM-28163 (150 nmol).
cFos IMMUNOHISTOCHEMISTRY, FEEDING, AND GH MEASUREMENTS
About 18–25-week-old male and female C57BL6/J and NPY-GFP
mice were individually housed and had free access to food and
water at the time of injections. Vehicle, native ghrelin (30 nmol),
BIM-28131 (30 nmol), BIM-28163 (150 nmol), or native ghrelin
(30 nmol) combined with BIM-28163 (150 nmol) were injected ip
in the early light phase (9.00 a.m.–11.00 a.m.).
A pre-weighed amount of food was distributed in each cage at
the time of injections and weighed 90 min later in order to confirm
the effects of the treatments on food consumption and to corre-
late food intake to the number of activated cFos nuclei. 15 min
following the injection, 4µl of whole blood was withdrawn from
the tail vein, homogenized in 116µl of GH buffer (PBS, 0.05%
Tween) for GH measurements. Whole blood GH concentrations
were evaluated by EIA as previously described (Steyn et al., 2011).
The number of nuclei immunoreactive for cFos protein were
quantified 90 min after ip injection of peptides to determine which
brain regions were activated by the compounds. Mice were deeply
anesthetized with pentobarbital (5.5 mg/30 g BW) and perfused
through the ascending aorta with saline 0.9% for 1 min followed
by 4% paraformaldehyde (PFA) in phosphate buffer 0.1 M (PB)
for an additional 9 min. The brains were removed, post-fixed for
2 h in 4% PFA and cryoprotected in 30% sucrose for 2 days at 4˚C.
Brains were then frozen in 2-methyl-butane and sectioned in the
coronal plane at a thickness of 25µm using a freezing microtome
(Frigomobile, Leica, Wetzlar, Germany).
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For the detection of cFos protein expression, free-floating
sections were processed for immunohistochemistry. Sections were
incubated in blocking buffer (10% Normal Donkey Serum, 0.3%
Triton X-100 in 0.1 M TBS) for 1 h at room temperature then
incubated with rabbit cFos antibody (1:20000, Ab-5, Jackson Lab-
oratories, West Grove, PA, USA) in 1% NDS, 0.3% Triton X-100 in
0.1 M TBS overnight at room temperature. Sections were then
rinsed 4× 10 min in 0.1 M TBS and incubated with Cy3 con-
jugated Donkey Anti-Rabbit antibody (1:800 DAR-Cy3, Jackson
Laboratories, West Grove, PA, USA) 1 h at room temperature and
then rinsed 4× 10 min in 0.1 M TBS. Sections were mounted
with fluoromount and quantified using a Zeiss Axioplan epiflu-
orescence microscope (Carl Zeiss, Le Pecq, France) under 40×
magnification. Quantifications were performed bilaterally every
100µm sections through the ArcN (2.3–1.6 mm anterior to the
interaural line) and ventromedial nucleus (VMH, 2.5–2.3 mm
anterior to the interaural line) of the hypothalamus and in the
NTS (3.7 mm posterior to the interaural line) and AP (3.7 mm
posterior to the interaural line) of the brainstem (Franklin and
Paxinos, 1997).
NPY neurons were visualized using GFP fluorescence. GFP-
positive cell bodies expressing cFos were quantified unilaterally
under 40×magnification using a confocal SP5 microscope (Leica,
Wetzlar, Germany). Co-localizations were determined with the
Image-J software (http://rsbweb.nih.gov/ij/) on series of contin-
uous optical sections with 0.5µm increment along the z-axis of
the section.
STATISTICAL ANALYSES
Values are given as mean± SEM. Statistical analyses were per-
formed using ANOVA, repeated measures ANOVA followed by
Fisher PLSD post hoc test using the Statview software (SAS Institute
Inc., Cary, NC, USA).
RESULTS
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON FEEDING
BEHAVIOR
Feeding was monitored after intraperitoneal injections of native
ghrelin (30 nmol), BIM-28163 (150 nmol), BIM-28131 (30 nmol),
or after co-administration of native ghrelin+BIM-28163 in the
early light phase. In a first subset of mice, feeding was monitored
manually after injection of the treatments in randomly assigned
groups of animals. Ninety minutes after the injections, a sig-
nificant effect of treatment on food consumption was observed
(Figure 1A). Although native ghrelin increased food intake by
twofold, the effect of this compound was not significant. Only
BIM-28131 and BIM-28163 increased food consumption signif-
icantly with BIM-28131 being three times more effective and
BIM-28163 two times more effective than ghrelin, respectively.
Food intake was identical after co-administration of BIM-28163
and native ghrelin or after administration of ghrelin alone. Auto-
mated feeding stations were also used to monitor cumulative food
intake and meal pattern during 7 h following the injection in a
second set of mice: animals received each treatment randomly in
a cross-over designed manner (Figure 2 and Table 1). When data
were analyzed as repeated measures in the same mouse and over
time, there was a significant interaction between time and treat-
ment. BIM-28131 was the only compound to stimulate appetite
even in mice that did not respond well to ghrelin. Increased food
consumption in this group was associated with a tendency to
increased meal number, total meal size, and total meal duration
(Table 1).
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FIGURE 1 | Effect of native ghrelin and BIM compounds on
cumulative food intake and GH secretion measured during the light
cycle in mice. Data represent mean±SEM. (A) Mean cumulative food
intake (90 min) after ip injection of native ghrelin (30 nmol), BIM-28131
(30 nmol), BIM-28163 (150 nmol), and native ghrelin (30 nmol)
co-administered with BIM-28163 (150 nmol). ANOVA shows an effect of
treatment on 90 min food intake: *p<0.05 BIM-28163 vs. vehicle,
**P < 0.01 BIM-28131 vs. vehicle, and native ghrelin, @P <0.05
BIM-28131 vs. native ghrelin+BIM-28163, Fisher PLSD post hoc test.
(B) GH secretion measured by tail bleeding 15 min after ip injection of
BIM compounds in the same animals. ANOVA shows an effect of
treatment on GH levels: **p<0.01 native ghrelin vs. vehicle,
***P <0.001 BIM-28131 vs. vehicle, @P <0.05 native ghrelin vs. native
ghrelin+BIM-28163, @@P <0.01 BIM-28131 vs. native ghrelin+
BIM-28163, ##P <0.01 native ghrelin or BIM-28131 vs. BIM-28163, Fisher
PLSD post hoc test.
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FIGURE 2 | Effect of native ghrelin and BIM compounds on cumulative
food intake measured with the automated feeding station in mice. Mean
cumulative food intake (0–7 h) after ip injection of native ghrelin (30 nmol),
BIM-28131 (30 nmol), BIM-28163 (150 nmol), and native ghrelin (30 nmol)
co-administered with BIM-28163 (150 nmol). Data represent mean±SEM.
Repeated measures ANOVA over time (7 h) and across treatments shows an
interaction between time and treatment on cumulative food intake. P =0.06
BIM-28131 vs. vehicle, Fisher PLSD post-hoc test.
Table 1 | Effect of native ghrelin and BIM compounds on meal pattern
measured with the automated feeding station in mice.
Meal
number
n=3
Total meal
size (g)
n=4
Total meal
duration (min)
n=4
Vehicle 1.25±0.75 0.23±0.15 7.50±4.97
Ghrelin 3.00±1.08 0.41±0.17 15.50±9.90
BIM-28131 4.00±0.41 0.82±0.10 31.50±4.99
BIM-28163 3.50±2.02 0.92±0.57 26.75±14.73
Ghrelin+BIM-28163 3.50±1.04 0.76±0.29 27.75±12.37
Meal number, total meal size, and total meal duration measured (0–7 h) after ip
injection of native ghrelin (30 nmol), BIM-28131 (30 nmol), BIM-28163 (150 nmol),
and native ghrelin (30 nmol) co-administered with BIM-28163 (150 nmol). Data
represent mean±SEM.
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON GH SECRETION
GH plasma levels were monitored 15 min following the injec-
tions in the same animals used to monitor food intake manually
(Figure 1B). Native ghrelin and BIM-28131 equally stimulated GH
secretion whereas GH secretion was not increased after injection
of BIM-28163 alone. In contrast to feeding data, BIM-28163
antagonized ghrelin-induced GH secretion.
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON cFos
ACTIVATION IN THE HYPOTHALAMIC ArcN
cFos activation was monitored after intraperitoneal injections
of native ghrelin (30 nmol), BIM-28163 (150 nmol), BIM-
28131 (30 nmol), or after co-administration of native ghre-
lin+BIM-28163 in the early light phase. Repeated mea-
sures ANOVA over the rostro-caudal extent of the ArcN
showed an effect of treatment on cFos immunoreactive nuclei
(Figure 3A). All treatment groups were significantly elevated
compared to the vehicle-treated group, except BIM-28163
which had a modest effect (Figure 3B). Injection of native
ghrelin induced cFos activation and this was not antago-
nized by co-administration of BIM-28163. Administration of
BIM-28131 induced a more pronounced activation than all
other treatments. Thus the efficiency of activation in the
ArcN was BIM-28131> native ghrelin> native ghrelin+BIM-
28163>BIM-28163. Differences were greater around 2.1–2.0 mm
anterior to the interaural line where most NPY neurons are
localized.
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FIGURE 3 | Effect of native ghrelin and BIM compounds on cFos
immunoreactivity in mice in the ArcN,AP, NTS, andVMH. (A) Number of
cFos immunoreactive nuclei and (B) sum of cFos immunoreactive nuclei
along the rostro-caudal extent of the ArcN (2.3–1.6 mm anterior to the
interaural line). Data represent mean±SEM. (A) Repeated measures ANOVA
over the rostro-caudal extent of the ArcN shows an effect of treatment on the
number of cFos-positive nuclei: P <0.0001 native ghrelin vs. Vehicle,
BIM-28163, and BIM-28131, P <0.0001 BIM-28131 vs. all other treatments,
P < 0.0001 BIM-28163 vs. all other treatments except vehicle, P <0.01
BIM-28163 vs. vehicle, P <0.0001 native ghrelin+BIM-28163 vs. vehicle,
BIM-28163, and BIM-28131, Fisher PLSD post hoc test. (B) ***P <0.001 vs.
vehicle, #P < 0.05 vs. BIM-28163, ##P <0.01 vs. BIM-28163, ###P <0.001 vs.
BIM-28163, @@P <0.01 vs. ghrelin+BIM-28163, Fisher PLSD post hoc test.
(C,D) Number of cFos immunoreactive nuclei in the NTS and AP (3.7 mm
posterior to the interaural line). Data represent mean±SEM. ANOVA shows
an effect of treatment on the number of cFos nuclei in the NTS and AP.
*P < 0.05, **P <0.01 and ***P <0.001 vs. vehicle, #P < 0.05 vs. 28163,
Fisher PLSD post hoc test. (E) Number of cFos immunoreactive nuclei in the
VMH (2.5–2.3 mm anterior to the interaural line). Data represent mean±SEM.
No significant effect of treatments is observed in the VMH. (F) Summary of
the effect of the different BIM compounds on cFos activation in the ArcN,
NTS, and AP. Cc, central canal.
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON cFos
ACTIVATION IN THE NTS AND AP OF THE BRAINSTEM
cFos activation was also observed in the AP and nucleus trac-
tus solitarius (NTS) (Figures 3C,D). In the NTS, in contrast
to the ArcN, all treatments significantly increased the number
of cFos-immunoreactive cells. BIM-28131 stimulated cFos as
efficiently as native ghrelin. BIM-28163 had an activity per se but
was inefficient in antagonizing ghrelin-induced cFos. In the AP, the
compounds had different activities. Native ghrelin and BIM-28131
had the same efficiency in activating cFos, but BIM-28163 was
ineffective.
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON cFos
ACTIVATION IN THE HYPOTHALAMIC VMH
In a separate group of animals, cFos activation was quan-
tified in the VMH (Interaural line: −2.5, −2.3). Due to
the high level of cFos activation and high variability in
vehicle-treated animals, statistical differences were not observed
between treatments (Figure 3E). The number of cFos nuclei
in vehicle, ghrelin, and BIM-28131-treated animals were iden-
tical; however, in mice treated with BIM-28163, the num-
ber of cFos nuclei was twice as elevated as in ghrelin-treated
mice.
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FIGURE 4 | Effect of native ghrelin and BIM compounds on cFos
immunoreactivity in ArcN NPY neurons in NPY-Renilla GFP mice.
Representative confocal microphotographs showing GFP neurons (green),
cFos nuclei (red), and the merge of both signals (yellow/orange) in coronal
sections of the ArcN at approximately 2.1–1.9 mm anterior to the interaural
line. Data represent mean±SEM. Scale bar represents 50µm in the ArcN.
3V, third ventricle; ME, median eminence.
EFFECT OF GHS-R1a AGONISTS AND ANTAGONISTS ON cFos
ACTIVATION IN NPY NEURONS
To measure cFos immunoreactivity in NPY neurons, we used NPY-
GFP mice. All treatments induced cFos activation in NPY neurons
as compared with vehicle-treated mice (Figure 4 and Table 2).
Treatments did not modify the number of GFP-positive neurons.
BIM-28131 and native ghrelin co-administered with BIM-28163
induced the greatest activation of NPY neurons with more than
20% of NPY cells activated, whereas native ghrelin and BIM-28163
alone induced cFos in less than 15% of NPY neurons (Table 2).
DISCUSSION
The present study demonstrates that two GHS-R1a synthetic lig-
ands, BIM-28163 and BIM-28131, are powerful stimulators of
appetite in mice, acting through pathways and brain regions that
are distinct from the ones activated by ghrelin (Figure 3F and
Table 3).
BIM-28163 is a full GHS-R1a antagonist as it has no intrinsic
activity at the GHS-R1a, and can fully block the ability of ghre-
lin to activate the GHS-R1a, as well as block ghrelin-induced GH
release, both in vitro and in vivo (Halem et al., 2004). It is thus
a pharmacological tool to dissect the role of endogenous ghre-
lin. However, whereas previous investigations in rats with this
GHS-R1a antagonist revealed a role of the endogenous ligand
in amplifying GH pulsatile pattern, blocking GHS-R1a fails to
inhibit food intake (Zizzari et al., 2005), and BIM-28163 even
stimulates appetite and weight gain after daily treatment in rats
(Halem et al., 2004, 2005). In the current study performed in mice,
we also demonstrate that acute injection of BIM-28163 increases
food consumption and show for the first time that the com-
pound induces cFos in two brain regions involved in the control
of appetite, the hypothalamus and brainstem. The feeding effect
of BIM-28163 is observed as early as 15–30 min after its injection
(i.e., same time-course as native ghrelin) (data not shown).
It was previously described in the rat that intraperitoneal (ip)
injection of native ghrelin in the early light phase induces feeding
and cFos activation in the ArcN, NTS, and AP (Hewson and Dick-
son, 2000; Lawrence et al., 2002; Takayama et al., 2007). A dose of
30 nmol/30 g body weight was chosen here based on a published
study showing that this dose stimulates food intake in mice (Ziz-
zari et al., 2007). Although ghrelin was very potent in activating
cFos in the ArcN, NTS, and AP in the present study, its effects on
feeding did not reach statistical significance. It may be due to the
fact that different sets of animals were used for feeding experi-
ments and cFos experiments. Another possible interpretation is
that cFos activation in these nuclei is required but not alone suffi-
cient to induce an effect on appetite. We indeed recently observed
that after ip injection of ghrelin, animals can be subdivided into
two groups: high and low responders, suggesting an interindivid-
ual variability in the feeding effects of ghrelin (Hassouna et al.,
2012b).
BIM-28131 is a super-agonist with regard to food intake in rats
(Strassburg et al., 2008; Palus et al., 2011). It is also very potent
to stimulate both appetite and cFos in the current study even in
mice that were not responsive to ghrelin in the cross-over designed
study. Differences in stability between native ghrelin and BIM-
28131 would partly explain the differential activities of these two
compounds. Indeed, in addition to a fivefold higher affinity than
native ghrelin in binding to the GHS-R1a and a 10-fold increased
potency in activating the receptor, BIM-28131 has a 10-fold greater
circulating half-life. However, BIM-28131 is comparable to ghrelin
with regard to stimulating GH secretion. The equal effect on GH
release may be possible because the action of the compounds may
be partly relayed at the pituitary level and the time of blood sam-
pling occurred after a relatively short time (15 min) whereas the
food intake was measured over 90 min or greater. By analyzing the
feeding response every 15 min following the injection, BIM-28131
did not have a stronger feeding effect over native ghrelin at 15–
30 min post-injection (data not shown) but from 60 min following
the injection. Thus, BIM-28131 is more powerful than ghrelin in
stimulating appetite at equimolar doses, and is also more pow-
erful in activating cFos in the ArcN, but not in the NTS and AP,
suggesting that the activity of this super-agonist is mostly medi-
ated in the ArcN. This is further substantiated by cFos activation
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Table 2 | Effect of native ghrelin and BIM compounds on the number of GFP-positive cells, number of cFos-positive nuclei, number, and
percentage of GFP-positive cells expressing cFos protein in the ArcN in NPY-Renilla GFP mice.
GFP-positive
cells
cFos-positive
nuclei
GFP-positive cells
expressing cFos
%GFP-positive cells
expressing cFos
Vehicle (n=5) 78.2±10.5 6.0±2.1 1.0±0.4 1.5±0.7
Ghrelin (n=4) 106.0±9.5 35.7±11.4* 14.8±5.8 13.9±4.9
BIM-28131 (n=4) 84.5±9.4 43.5±7.6** 18.0±4.9* 20.7±3.9**
BIM-28163 (n=4) 102.5±14.9 24.2±7.5 11.5±4.1 11.9±3.7
Ghrelin+BIM-28163 (n=4) 81.2±23.1 30.2±8.6* 16.0±7.7* 23.4±7.5**
Coronal sections of the ArcN at approximately 2.0–1.9 mm anterior to the interaural line were quantified unilaterally. Data represent mean±SEM.
*P<0.05 and **P<0.01 vs. vehicle.
Table 3 | Summary of the effects of the different BIM compounds on GH secretion, food intake, and cFos activity in the ArcN, NTS, and AP after
intraperitoneal administration in the mouse.
Food intake GH secretion cfos ArcN cfos AP cfos NTS cfosVMH
Ghrelin ± +++ ++ +++ +++ =
28131 +++ +++ +++ +++ +++ =
28163 ++ = ± ± +++ =
Ghrelin+28163 No antagonistic action Antagonistic action No antagonistic action No antagonistic action No antagonistic action =
Food intake and cFos measured 90 min and GH 15 min post-injection.
in orexigenic NPY ArcN neurons in BIM-28131-treated mice as
compared with ghrelin-treated ones. NPY neurons are well-known
targets for ghrelin actions (Tannenbaum et al., 2003; Chen et al.,
2004) and induction of cFos in NPY neurons in rats was previously
demonstrated with other ghrelin agonists (Dickson and Luckman,
1997).
In the current study, BIM-28163 activates several brain nuclei.
The intensity of activation seems to be different depending on the
region and relative to that of native ghrelin. BIM-28163 appears
to have greater activity in the NTS than in the ArcN and AP, two
structures outside the blood brain barrier (BBB). Indeed, in the
NTS, BIM-28163 is as potent as both native ghrelin and BIM-
28131 in inducing cFos with more than a twofold increase as
compared with saline treated animals although the effect does not
reach statistical significance. In the ArcN, however, BIM-28163 is
not as effective as ghrelin in stimulating cFos, and is much less
active than BIM-28131. This suggests that BIM-28163 uses alter-
native pathways other than through these BBB free structures to
relay its orexigenic actions. These data are consistent with previous
reports in rats showing that BIM-28163 selectively activates cFos
in the DMH after icv injections, whereas, in the ArcN, it acts exclu-
sively as an antagonist by blocking ghrelin-induced cFos activation
without any intrinsic effect (Halem et al., 2004, 2005). Our data
here slightly differ from the above studies in rats because BIM-
28163 still activates cFos in the ArcN, although to a much lesser
extent than ghrelin. In addition, we were not able to observe any
antagonistic actions of BIM-28163 either on food intake or cFos
activity when co-administered with ghrelin. Differences may be
due to the species studied (mouse vs. rat), to the mode of admin-
istration (ip vs. icv), as well as the dose injected (5 nmol/g ip vs.
1.5 nmol/rat icv).
Differences in antagonizing ghrelin-induced food consump-
tion or cFos may be due to the fact that BIM-28163 was injected
at a fivefold higher dose than ghrelin instead of a 10-fold higher
dose (IC50 for BIM-28163 at GHS-R1a is 10-fold higher than for
native ghrelin). However, the antagonistic effect of BIM-28163 on
ghrelin-induced cFos activity in rats was still observed when BIM-
28163 was administered at a fivefold dose (Halem et al., 2005). The
recent report by Costantini et al. (2011) shows that another novel
and selective GHS-R1a antagonist with no partial agonist activity,
GSK1614343 was also not able to antagonize ghrelin-induced food
intake at a dose of 10 mg/kg.
Concerning the VMH, a high level of activation and high
interindividual variability in vehicle-treated animals are observed.
Consequently, ghrelin seems to have no stimulatory action in
this nucleus. This is consistent with other data in rats show-
ing that ghrelin does not activate cFos in the VMH (Lawrence
et al., 2002). In contrast, the number of cFos-positive nuclei after
treatment with BIM-28163 is almost twofold higher than in the
ghrelin-treated group.
Within the hypothalamus, the ArcN is one of the main tar-
gets of peripheral signals, such as leptin and ghrelin, which relay
information about energy stores and/or nutritional status. The
efficiency of the compounds used in this study in activating
the ArcN is BIM-28131> native ghrelin> native ghrelin+BIM-
28163>BIM-28163. The GHS-R1a has been shown to be co-
expressed with several neuropeptides in the ArcN. It is expressed
on the orexigenic NPY and GHRH neurons (Willesen et al., 1999;
Tannenbaum et al., 2003) and these populations of neurons relay
ghrelin orexigenic and GH-releasing actions in rats (Tannenbaum
et al., 2003; Chen et al., 2004). In mice, ghrelin also induces cFos
in NPY-expressing neurons (Wang et al., 2002). To determine
whether BIM-28163 and BIM-28131 orexigenic actions could be
partly mediated through NPY neurons as is the case for ghre-
lin, we investigated the effect of these compounds in NPY-GFP
mice. Indeed, ip administration of 30 nmol ghrelin during the light
www.frontiersin.org March 2013 | Volume 4 | Article 25 | 7
Hassouna et al. Ghrelin mimetics: growth and feeding
cycle induced cFos activation in approximately 26% of NPY neu-
rons (Hassouna et al., 2012a,b). Here we observed that about 15%
of NPY-positive cells were activated after BIM-28163 or native
ghrelin administration whereas about 20% were activated after
BIM-28131 treatment. The orexigenic action of BIM-28163 could
be partly mediated through an activation of ArcN NPY neurons.
Orexigenic actions of ghrelin may also be mediated by a reduced
activity in POMC cells (Cowley et al., 2003). Modified activity
of the anorexigenic POMC neurons after treatment with GHS-
R1a compounds can thus not be excluded. Orexigenic actions of
GSK1614343, another GHS-R1a antagonist, was accompanied by a
reduced expression of POMC in the ArcN after chronic treatment
with the compound (Costantini et al., 2011).
Although the majority of studies demonstrated that acylation
is essential for ghrelin feeding activities (Inhoff et al., 2009), one
study showed that desacyl ghrelin was able to stimulate food
intake after intracerebroventricular administration by a mecha-
nisms independent of the GHS-R1a (Toshinai et al., 2006). Inter-
estingly, feeding effects of desacyl ghrelin was more pronounced in
GHS-R1a deficient mice. Thus it can be postulated that blocking
the GHS-R1a with the antagonist may allow desacyl to stimu-
late feeding through a GHS-R1a independent pathway. Whereas a
distinct receptor from the known GHS-R1a would possibly medi-
ate the orexigenic actions of BIM-28163, we can not exclude
that these effects are also dependent on the GHS-R1a. Indeed,
a recent study using the antagonist, GSK1614343, showed that
the appetite-mediated action of this compound was abolished in
GHS-R null mice (Costantini et al., 2011), suggesting that the
orexigenic effects of GSK1614343 is relayed by GHS-R1a or that
the ghrelin receptor may be needed. GHS-R1a is associated with
multiple signal transduction pathways (Carreira et al., 2004; Holst
et al., 2005) and it is possible that BIM-28163 could activate a
specific pathway on the GHS-R1a that is independent from the
one mediating GH-releasing activities. In addition, the formation
of heterodimers between the GHS-R1a and other receptors has
been evidenced (Kern et al., 2012), and raises the question as to
whether the orexigenic actions of BIM-28163 could be mediated
through interaction with a GHS-R1a dimer that differs from the
GHS-R1a receptor form that regulates GH secretion. BIM-28163
could possibly interact with a receptor that needs to dimerize with
the GHS-R1a.
The present study demonstrates that two GHS-R1a synthetic
ligands, BIM-28163, and BIM-28131, are powerful stimulators of
appetite in mice, acting through pathways and brain regions that
are distinct from those activated by ghrelin.
In conclusion, utilization of synthetic GHS-R1a ligands, such
as BIM-28163 and BIM-28131 that are powerful stimulators
of appetite and act through pathways that are distinct from
those activated by ghrelin, even in situations when ghrelin seems
modestly effective, can have important clinical implications, in
conditions such as cachexia or anorexia [see other chapter in
the same issue: Ghrelin: Central and Peripheral Implications in
Anorexia Nervosa (Mequinion et al., 2012)]. BIM-28131 was pre-
viously demonstrated to be very efficient in a rat heart failure
model of cachexia (Strassburg et al., 2008; Palus et al., 2011).
In addition, observations that BIM-28163 is able to selectively
stimulate feeding and increase weight gain without altering GH
secretion may suggest the possibility of treating pathologies in
which hyper-activity of the GH/IGF-1 axis may be deleterious.
A better understanding of the molecular pathways activated by
these compounds will be useful for devising future therapeutic
applications.
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